Simulations Plus Inc(SLP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | 46.02 | EPS (ttm) | 0.4 | Insider Own | 17.18% | Shs Outstand | 20.2M | Perf Week | - |
| Market Cap | 0.37B | Forward P/E | 20.35 | EPS next Y | 5.85% | Insider Trans | -1.38% | Shs Float | 16.8M | Perf Month | 0.55% |
| Enterprise Value | 0.32B | PEG | - | EPS next Q | 0.11 | Inst Own | 90.62% | Short Float | 16.94% | Perf Quarter | 11.7% |
| Income | 0.01B | P/S | 4.54 | EPS this Y | -16.99% | Inst Trans | -1.9% | Short Ratio | 6.81 | Perf Half Y | 49.39% |
| Sales | 0.08B | P/B | 2.68 | EPS next 5Y | - | ROA | 5.64% | Short Interest | 2.84M | Perf YTD | 1.04% |
| Book/sh | 6.88 | P/C | 7.45 | EPS past 3/5Y | - | ROE | 6.17% | 52W High | -12.33% ($21.01) | Perf Year | 28.27% |
| Cash/sh | 2.47 | P/FCF | 15.18 | Sales past 3/5Y | 13.67% 13.74% | ROIC | 5.81% | 52W Low | 66.1% ($11.09) | Perf 3Y | -56.01% |
| Dividend Est. | - | EV/EBITDA | 18.15 | EPS Y/Y TTM | 112.78% | Gross Margin | 62.4% | Volatility(W/M) | 0.13% 0.17% | Perf 5Y | -58.92% |
| Dividend TTM | - | EV/Sales | 3.94 | Sales Y/Y TTM | 2.08% | Oper. Margin | 14.63% | ATR (14) | 0.05 | Perf 10Y | 106.5% |
| Dividend Ex-Date | 2024/7/29 | Quick Ratio | 5.54 | EPS Q/Q | 105.28% | Profit Margin | 9.88% | RSI (14) | 62.34 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.54 | Sales Q/Q | 7.48% | SMA20 | 0.11% ($18.4) | Beta | 1.31 | Target Price | $17.25 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/7/9 | SMA50 | 0.45% ($18.34) | Rel Volume | 0.32 | Prev Close | $18.42 |
| Employees | 213 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 29.03% 4.74% | SMA200 | 12.45% ($16.38) | Avg Volume(3M) | 0.42M | Price | $18.42 |
| IPO | 1997/6/18 | Option/Short | Yes/Yes | Trades | 1463 | Volume | 133,567 | Change | - |
Company
SLP is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A pharmaceutical simulation software company that uses computer modeling to predict the absorption, distribution, metabolism, and excretion (ADME) of drugs during the drug development process. A leading company in the field of physiologically based pharmacokinetic (PBPK) modeling, its flagship product, GastroPlus, is deeply embedded in the regulatory review workflow for new drugs.
Over the past 1 year, roughly in the middle
12% below its 1-year high.
SLP makes money exceptionally well
14.63% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -17.0% this year.
Tap to view numbers
The price looks about right
Trading at 46.0 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -56.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 90.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
AFSM 0.00%
XDAT 0.00%
IWC 0.00%
JPSE 0.00%
HAPS 0.00%It ranks #4 in the industry
Based on market cap of $373M.
SLP $373M PER 46.0
VEEV $42B PER 43.2
BTSG $12B PER 43.9
TEM $11B PER -
FAQ
What kind of company is SLP?
SLP belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of SLP?
The market cap of SLP is approximately $373M, ranking 3,480 within its sector.
What is the P/E ratio of SLP?
SLP has a P/E ratio of approximately 46.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for SLP?
SLP has recorded a 52-week high of $21.01 and a low of $11.09.
